Vertex director sells shares, receives stock award

Vertex Pharmaceuticals director Dr. Sangeeta N. Bhatia reported two common stock transactions.

Rhea-AI Filing Summary

Vertex Pharmaceuticals director Dr. Sangeeta N. Bhatia reported two common stock transactions. She received a grant of 943 shares as a restricted stock unit award that will vest, subject to limited exceptions, on the first anniversary of the grant date. She also completed an open-market sale of 318 shares at $423.73 per share under a company-approved trading plan pursuant to Rule 10b5-1, which was entered into on 05/27/2025. After these transactions, she directly holds 4,924 shares of Vertex common stock.

Insider Trade Summary 10b5-1

Net Seller: 318 shares

Net Sell 2 txns

Insider Bhatia Sangeeta N.

Role Director

Sold 318 shs ($135K)

Type	Security	Shares	Price	Value
Sale	Common Stock	318	$423.73	$135K
Grant/Award	Common Stock	943	$0.00	$0.00

Holdings After Transaction: Common Stock — 4,924 shares (Direct)

Footnotes (2)

1. F1. Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
2. F2. Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025.

Key Figures

Shares sold: 318 shares Sale price: $423.73 per share RSU award size: 943 shares +2 more

5 metrics

Shares sold 318 shares Open-market sale of common stock

Sale price $423.73 per share Price for 318-share sale

RSU award size 943 shares Restricted stock unit grant to director

Shares held after transactions 4,924 shares Direct holdings of common stock post-trade

Net share change 318 shares net-sell Net shares sold across reported transactions

Key Terms

restricted stock unit award, Rule 10b5-1, open-market sale

3 terms

restricted stock unit award financial

"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

Rule 10b5-1 regulatory

"company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VRTX director Sangeeta Bhatia report?

Dr. Sangeeta N. Bhatia reported a grant of 943 shares of Vertex common stock as a restricted stock unit award and an open-market sale of 318 shares at $423.73 per share. Following these transactions, she directly holds 4,924 shares.

How many VRTX shares did Sangeeta Bhatia sell and at what price?

Dr. Bhatia sold 318 shares of Vertex common stock in an open-market transaction at $423.73 per share. The sale was executed under a company-approved trading plan pursuant to Rule 10b5-1 entered into on 05/27/2025.

What stock award did Sangeeta Bhatia receive from Vertex (VRTX)?

She received a restricted stock unit award covering 943 shares of Vertex common stock. This award is scheduled to vest, subject to certain limited exceptions, on the first anniversary of the grant date, providing additional equity-based compensation as a director.

How many VRTX shares does Sangeeta Bhatia hold after these transactions?

After the reported grant and sale, Dr. Bhatia directly holds 4,924 shares of Vertex common stock. This figure reflects her position following the 943-share restricted stock unit award and the open-market sale of 318 shares.

Was the VRTX share sale by Sangeeta Bhatia under a Rule 10b5-1 plan?

Yes. The 318-share sale of Vertex common stock was made under Dr. Bhatia’s company-approved trading plan pursuant to Rule 10b5-1, which she entered into on 05/27/2025, indicating the transaction was pre-arranged.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 04:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhatia Sangeeta N.

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		A		943(1)	A	$0	5,242	D
Common Stock	05/04/2026		S(2)		318	D	$423.73	4,924	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

2. Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)